Arca
Skip to content
Tools
Tools

Label Changes: Mounjaro (tirzepatide)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Mounjaro label DailyMed has published, from Eli Lilly and Company, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 22
  • Sections changed, version 38 to 40: 10

What changed from version 38 to version 40

May 6, 2026 to Sep 2, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 39 words added, 3 removed
  2. Dosage and administrationChanged · 106 words added, 120 removed
  3. Warnings and precautionsChanged · 29 words added, 52 removed
  4. Adverse reactionsChanged · 491 words added, 352 removed
  5. Use in specific populationsChanged · 79 words added, 27 removed
  6. Clinical pharmacologyChanged · 44 words added, 1 removed
  7. Clinical studiesChanged · 792 words added, 4 removed
  8. How suppliedChanged · 2 words added, 1 removed
  9. Patient counseling informationChanged · 171 words added, 142 removed
  10. Medication guideChanged · 35 words added, 5 removed

Indications and usage

Changed39 words added, 3 removed
1 INDICATIONS AND USAGE
MOUNJARO® is indicated:
MOUNJARO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.

Dosage and administration

Changed106 words added, 120 removed
1 unchanged line
2.1 Recommended Dosage
The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly [see Dosage and Administration (2.2)]. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)]. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.
Follow the starting dosage recommendation and dosage escalation schedule below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)].
Recommended Starting Dosage and Escalation
After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.
The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly [see Dosage and Administration (2.2)].
If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients.
If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.
The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients.
Recommendations Regarding Missed Doses
If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
5 unchanged lines
Administer MOUNJARO once weekly, any time of day, with or without meals.
Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person should inject MOUNJARO in the back of the upper arm.
Rotate injection sites with each dose.
2 unchanged lines

Warnings and precautions

Changed29 words added, 52 removed
20 unchanged lines
5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. MOUNJARO has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
5.8 Acute Gallbladder Disease
7 unchanged lines

Adverse reactions

Changed491 words added, 352 removed
17 unchanged lines
Adverse reactions were also evaluated in a larger pool of adult patients with type 2 diabetes mellitus participating in seven controlled clinical trials which included two placebo-controlled trials (SURPASS-1 and -5), three trials of MOUNJARO in combination with metformin, sulfonylureas, and/or SGLT2 Inhibitors (SURPASS-2, -3, -4) [see Clinical Studies (14.3)] and two additional trials conducted in Japan. In this pool, a total of 5119 adult patients with type 2 diabetes mellitus were treated with MOUNJARO for a mean duration of 48.1 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 58% were male. The population was 65% White, 24% Asian, 7% American Indian or Alaska Native, and 3% Black or African American; 38% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.3%. As assessed by baseline fundoscopic examination, 15% of the population had retinopathy. At baseline, eGFR was ≥90 mL/min/1.73 m2 in 52%, 60 to 90 mL/min/1.73 m2 in 40%, 45 to 60 mL/min/1.73 m2 in 6%, and 30 to 45 mL/min/1.73 m2 in 1% of patients.
Common Adverse Reactions in Adults
Table 1 shows common adverse reactions, not including hypoglycemia, associated with the use of MOUNJARO in the pool of placebo-controlled trials in adults. These adverse reactions occurred more commonly on MOUNJARO than on placebo and occurred in at least 5% of patients treated with MOUNJARO.
10 unchanged lines
In the pool of seven clinical trials in adults, the types and frequency of common adverse reactions, not including hypoglycemia, were similar to those listed in Table 1.
In a CV outcomes trial of 6,647 adults with type 2 diabetes mellitus and established CV disease exposed to MOUNJARO, adverse reactions reported with MOUNJARO were similar with the exception of dysesthesia (0.7%), decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%), and fatigue (10%) [see Clinical Studies (14.6)].
Gastrointestinal Adverse Reactions
1 unchanged line
The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated adult patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).
Other Adverse Reactions in Adults
Adverse Reactions in the Clinical Trial of Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus
MOUNJARO was administered to 97 pediatric patients 10 years of age and older with type 2 diabetes mellitus for a mean duration of 39.9 weeks [see Clinical Studies (14.5)]. The mean age was 15 years and 61% of patients were female. The population was 58% White, 11% Black or African American, 6% Asian, 20% American Indian or Alaska Native, and 5% were other races; 66% identified as Hispanic or Latino ethnicity. At baseline, pediatric patients had type 2 diabetes mellitus for an average of 2.4 years with a mean HbA1c of 8.0%.
The incidences of adverse reactions reported in pediatric patients treated with MOUNJARO 5 mg and 10 mg subcutaneously once-weekly were consistent with those described above for adult patients with type 2 diabetes mellitus with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. During the 30-week placebo-controlled period of the study, vomiting occurred in 3%, 16%, and 12% of patients and abdominal pain occurred in 9%, 22%, and 15% of patients treated with placebo, MOUNJARO 5 mg, and 10 mg, respectively.
Other Adverse Reactions in Adults and Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus
Hypoglycemia
Adults with Type 2 Diabetes Mellitus
Table 2 summarizes the incidence of hypoglycemic events in the placebo-controlled trials in adults.
13 unchanged lines
Hypoglycemia was more frequent when MOUNJARO was used in combination with a sulfonylurea [see Clinical Studies (14)]. In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.
Pediatric Patients 10 years of Age and Older with Type 2 Diabetes Mellitus
No severe hypoglycemia episodes were reported during the trial in pediatric patients 10 years of age and older with type 2 diabetes mellitus. Table 3 summarizes the incidence of hypoglycemic events with blood glucose <54 mg/dL in this trial.
Table 3: Hypoglycemia Adverse Reactions in the 30 Week Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus
Note: Percentages reflect the number of patients who reported at least 1 episode of blood glucose <54 mg/dL.
a Events after the introduction of a new glucose-lowering treatment are excluded.
| Placebo % | MOUNJARO 5 mg % | MOUNJARO 10 mg %
Add on to basal insulin with or without metformina | N=10 | N=10 | N=11
Blood glucose <54 mg/dL | 10 | 30 | 27
Add on to metformin alonea | N=24 | N=22 | N=22
Blood glucose <54 mg/dL | 4 | 9 | 9
Acute Pancreatitis
1 unchanged line
Heart Rate Increase
In the pool of placebo-controlled trials, treatment ofin adults, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. The clinical relevance of heart rate increases is uncertain.
Hypersensitivity Reactions
7 unchanged lines
Dysesthesia
In the pool of placebo-controlled clinical trials in adults, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo. In a CV outcomes trial, 0.7% of MOUNJARO-treated patients reported dysesthesia.
Dysgeusia
2 unchanged lines
Amylase and Lipase Increase
In the pool of placebo-controlled adult clinical trials in adults, treatment with MOUNJARO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 33% to 38% and serum lipase concentrations of 31% to 42%. Placebo-treated patients had a mean increase from baseline in pancreatic amylase of 4% and no changes were observed in lipase. The clinical significance of elevations in lipase or amylase with MOUNJARO is unknown in the absence of other signs and symptoms of pancreatitis.
Adverse Reactions in the Clinical Trial of Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus
MOUNJARO was administered to 97 pediatric patients 10 years of age and older with type 2 diabetes mellitus for a mean duration of 39.9 weeks [see Clinical Studies (14.5)]. The mean age was 15 years and 61% of patients were female. The population was 58% White, 11% Black or African American, 6% Asian, 20% American Indian or Alaska Native, and 5% were other races; 66% identified as Hispanic or Latino ethnicity. At baseline, pediatric patients had type 2 diabetes mellitus for an average of 2.4 years with a mean HbA1c of 8.0%.
The incidences of adverse reactions reported in pediatric patients treated with MOUNJARO 5 mg and 10 mg subcutaneously once-weekly were consistent with those described above for adult patients with type 2 diabetes mellitus with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. During the 30-week placebo-controlled period of the study, vomiting occurred in 3%, 16%, and 12% of patients and abdominal pain occurred in 9%, 22%, and 15% of patients treated with placebo, MOUNJARO 5 mg, and 10 mg, respectively.
No severe hypoglycemia episodes were reported during the trial. Table 3 summarizes the incidence of hypoglycemic events with blood glucose <54 mg/dL in the trial.
Table 3: Hypoglycemia Adverse Reactions in the 30 Week Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus
Note: Percentages reflect the number of patients who reported at least 1 episode of blood glucose <54 mg/dL.
a Events after the introduction of a new glucose-lowering treatment are excluded.
| Placebo % | MOUNJARO 5 mg % | MOUNJARO 10 mg %
Add on to basal insulin with or without metformina | N=10 | N=10 | N=11
Blood glucose <54 mg/dL | 10 | 30 | 27
Add on to metformin alonea | N=24 | N=22 | N=22
Blood glucose <54 mg/dL | 4 | 9 | 9
In a CV outcomes trial, treatment with MOUNJARO resulted in mean increases from baseline in pancreatic amylase of 29% and lipase of 28%.
6.2 Postmarketing Experience
6 unchanged lines

Use in specific populations

Changed79 words added, 27 removed
24 unchanged lines
8.5 Geriatric Use
In the pool of seven clinical trials, 15391,539 (30.1%) MOUNJARO-treated patients were 65 years of age or older, and 212 (4.1%) MOUNJARO-treated patients were 75 years of age or older at baseline [see Adverse Reactions (6.1), Clinical Studies (14.2, 14.3, 14.4)].
In a CV outcomes trial, 3,327 (50%) of MOUNJARO-treated patients were 65 years of age or older, and 705 (11%) of MOUNJARO-treated patients were 75 years of age or older at baseline [see Clinical Studies (14.6)].
No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
No overall differences in safety or effectiveness of MOUNJARO have been observed between patients 65 years of age and older and younger adult patients.
8.6 Renal Impairment
3 unchanged lines

Clinical pharmacology

Changed44 words added, 1 removed
13 unchanged lines
Gastric Emptying
Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. Tirzepatide slows post-meal glucose absorption, reducingand reduces postprandial glucose.
Exposure-Response Relationships
Exposure-response analyses integrating phase 2 and phase 3 efficacy data predict that after 52 weeks, tirzepatide 2.5 mg administered once weekly may reduce HbA1c by approximately 1.8% and fasting plasma glucose by approximately 43 mg/dL.
12.3 Pharmacokinetics
32 unchanged lines

Clinical studies

Changed792 words added, 4 removed
30 unchanged lines
Add-on to metformin
SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 18791,879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly.
Patients had a mean age of 57 years and 47% were men. The mean duration of type 2 diabetes mellitus was 8.6 years, and the mean BMI was 34 kg/m2. Overall, 83% were White, 4% were Black or African American, and 1% were Asian; 70% identified as Hispanic or Latino ethnicity.
29 unchanged lines
Add-on to metformin with or without SGLT2 inhibitor
SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 14441,444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily. In this trial, 32% of patients were on SGLT2 inhibitor. Insulin degludec was initiated at 10 units once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 26% of patients randomized to insulin degludec achieved the fasting serum glucose target of <90 mg/dL, and the mean daily insulin degludec dose was 49 U (0.5 U per kilogram).
Patients had a mean age of 57 years, and 56% were men. The mean duration of type 2 diabetes mellitus was 8.4 years, and the mean baseline BMI was 34 kg/m2. Overall, 91% were White, 3% were Black or African American, and 5% were Asian; 29% identified as Hispanic or Latino ethnicity.
20 unchanged lines
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor)
SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascularCV risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%).
Patients had a mean age of 64 years, and 63% were men. The mean duration of type 2 diabetes mellitus was 11.8 years, and the mean baseline BMI was 33 kg/m2. Overall, 82% were White, 4% were Black or African American, and 4% were Asian; 48% identified as Hispanic or Latino ethnicity. Across all treatment groups, 87% had a history of cardiovascularCV disease. At baseline, eGFR was ≥90 mL/min/1.73 m2 in 43%, 60 to 90 mL/min/1.73 m2 in 40%, 45 to 60 mL/min/1.73 m2 in 10%, and 30 to 45 mL/min/1.73 m2 in 6% of patients.
Insulin glargine was initiated at 10 U once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 30% of patients randomized to insulin glargine achieved the fasting serum glucose target of <100 mg/dL, and the mean daily insulin glargine dose was 44 U (0.5 U per kilogram).
70 unchanged lines
Difference from placebo (%)b (95% CI) | -- | -6.4c (-9.5, -3.2) | -10.3c (-13.5, -7.1) | -8.3c (-11.0, -5.6)
14.6 Cardiovascular Outcomes Trial of MOUNJARO in Adults with Type 2 Diabetes Mellitus and Established Cardiovascular Disease
SURPASS-CVOT (NCT04255433) was a Phase 3, event-driven, multicenter, international, randomized, double-blind, active comparator controlled, parallel-group study. In this trial, 13,299 patients with inadequately controlled type 2 diabetes mellitus and established CV disease were randomized to once weekly subcutaneous MOUNJARO (up to 15 mg) versus once weekly subcutaneous dulaglutide (1.5 mg), a GLP-1 receptor agonist indicated for glycemic control and to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus who have established CV disease or multiple CV risk factors. MOUNJARO was initiated at a dosage of 2.5 mg once weekly and increased by 2.5 mg every 4 weeks to a maximum dosage of 15 mg once weekly or the maximum tolerated dose. The dose of dulaglutide was initiated and maintained at 1.5 mg once weekly. The primary endpoint was the time to first occurrence of a three-part composite MACE outcome of CV death, MI, or stroke (MACE-3).
Patients eligible to enroll in the trial had type 2 diabetes mellitus and established CV disease, were 40 years of age or older, had a HbA1c of ≥7.0% and ≤10.5%, and a BMI ≥ 25 kg/m2. The mean age was 64 years, the mean duration of type 2 diabetes mellitus was 15 years, the mean HbA1c concentration was 8.4%, and the mean BMI was 33 kg/m2. Overall, 71% of patients enrolled were male; 82% were White, 2% were Black or African American, and 9% were Asian; 30% identified Hispanic or Latino ethnicity.
Patients reported the following types of CV disease at baseline: coronary artery disease (65%); prior coronary revascularization (57%); prior MI (47%); peripheral arterial disease (25%); prior lower extremity arterial revascularization (6%); prior stroke (19%); prior carotid revascularization (3%); and prior heart failure (20%). Of patients enrolled in the study, 20% had diabetic neuropathy, 2% had proliferative diabetic retinopathy, and 29% had non-proliferative diabetic retinopathy. The percentage of patients with an eGFR < 60 mL/min/1.73 m2 was 23%.
The most common antihyperglycemic medications taken at baseline were: metformin (81%), sodium-glucose cotransporter-2 (SGLT-2) inhibitors (31%), sulfonylureas (22%), and insulins (49%). At baseline CV disease and CV risk factors were managed with: statins (86%), antiplatelet therapies (83%), beta blockers (65%), angiotensin-converting enzyme (ACE) inhibitors (40%), and angiotensin receptor blockers (40%). During the trial, investigators were to modify anti-hyperglycemic and CV medications to achieve local standard of care treatment targets with respect to blood glucose, lipids, and blood pressure.
Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established. In this trial, 98% of participants had a complete assessment for the primary endpoint and 99.7% had vital status established. Refer to Figure 3 and Table 10.
Figure 3: Kaplan-Meier Curve: Time to First Occurrence of a MACE-3 (CV death, non-fatal MI, or non-fatal stroke) in the SURPASS-CVOT Trial
Table 10: Treatment Effect for MACE and All Cause Death, All Randomized and Treated Participants, Median Study Observation Time 210.1 weeks
a 95.3% confidence interval for the MACE-3 composite endpoint of CV death, non-fatal MI, or non-fatal stroke
b Cox-proportional hazards models with treatment as a factor and stratified for SGLT2i use.
c p=0.007 for noninferiority of MOUNJARO to dulaglutide
d Not controlled for family-wise type I error rate
| Dulaglutide N=6,647 (%) | MOUNJARO N=6,647 (%) | Hazard ratio vs Dulaglutide (95% CI)
MACE-3 (Composite of time to first occurrence of CV death, non-fatal MI, or non-fatal stroke)a,b,c | 863 (13.0) | 803 (12.1) | 0.92 (0.83, 1.01)
CV Deathd | 409 (6.2) | 367 (5.5) | 0.89 (0.77, 1.02)
Non-Fatal MId | 310 (4.7) | 292 (4.4) | 0.93 (0.80, 1.09)
Non-Fatal Stroked | 221 (3.3) | 215 (3.2) | 0.97 (0.80, 1.16)
Fatal or Non-Fatal MId | 358 (5.4) | 313 (4.7) | 0.87 (0.74, 1.01)
Fatal or Non-Fatal Stroked | 249 (3.7) | 229 (3.4) | 0.91 (0.76, 1.09)
All-Cause Deathd | 670 (10.1) | 567 (8.5) | 0.84 (0.75, 0.94)
Reductions from baseline in HbA1c and body weight were observed with MOUNJARO and dulaglutide treatment at Month 36.

How supplied

Changed2 words added, 1 removed
33 unchanged lines
If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.
Discard the single-dose pen andor single-dose vial after a total of 21 days at room temperature.
MOUNJARO Multi-dose Vial or Single-Patient-Use KwikPen
6 unchanged lines

Patient counseling information

Changed171 words added, 142 removed
26 unchanged lines
Administration
Instruct patients how to prepare and administer the correct dose of MOUNJARO and assess their ability to inject subcutaneously to ensure the proper administration of MOUNJARO. Inform patients and their caregiver(s) which
Instruct patients how to prepare and administer the correct dose of MOUNJARO and assess their ability to inject subcutaneously to ensure the proper administration of MOUNJARO. Instruct patients using MOUNJARO vials to always use a new syringe and needle for each injection. Use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose). Notify the patient of which MOUNJARO presentation they will be receiving and ensure training is appropriate for the specific MOUNJARO presentation. Advise patients to refer to the IFU in case of any change in the presentation. Advise caregivers that MOUNJARO KwikPen is not recommended for self-administration by pediatric patients or those with visual impairment unless their healthcare provider determines the patient can properly administer. [see Dosage and Administration (2.2)].
MOUNJARO presentation (e.g., single-dose pen or vial, multi-dose vial, single-patient use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation. Advise caregivers that MOUNJARO KwikPen is not recommended for self-administration by pediatric patients or those with visual impairment unless their healthcare provider determines the patient can properly administer. Instruct patients using MOUNJARO vials to always use a new syringe and needle for each injection and to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) [see Dosage and Administration (2.2)].
Missed Doses
2 unchanged lines
Pat.: www.lilly.com/patents
MOU-0011-USPI-20260422
MOU-0012-USPI-20260827

Medication guide

Changed35 words added, 5 removed
Mounjaro Medication Guide
This Medication Guide has been approved by the U.S. Food and Drug Administration | Revised: AprilAugust 2026
Medication Guide MOUNJARO® [mown-JAHR-OH] (tirzepatide) injection, for subcutaneous use
1 unchanged line
What is the most important information I should know about MOUNJARO? MOUNJARO may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats, MOUNJARO and medicines that work like MOUNJARO caused thyroid tumors, including thyroid cancer. It is not known if MOUNJARO will cause thyroid tumors, or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not use MOUNJARO if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
What is MOUNJARO? MOUNJARO is an injectable prescription medicine that is used: along with diet and exercise to improve blood sugar (glucose) in adults and children 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes mellitus who are at high risk for these events. It is not known if MOUNJARO is safe and effective for use in children under 10 years of age.
Do not use MOUNJARO if: you or any of your family have ever had a type of thyroid cancer called MTC or if you have an endocrine system condition called MEN 2. you have had a serious allergic reaction to tirzepatide or any of the ingredients in MOUNJARO. See the end of this Medication Guide for a complete list of ingredients in MOUNJARO. See " What are the possible side effects of MOUNJARO? " for symptoms of a serious allergic reaction.
16 unchanged lines
What are the ingredients in MOUNJARO? Active ingredient: tirzepatide Inactive ingredients: sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection. Benzyl alcohol, glycerin, and phenol are also inactive ingredients in the multi-dose vial and single-patient-use KwikPen. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. MOUNJARO® and KwikPen® are registered trademarks of Eli Lilly and Company. Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA Copyright © 2022, 2026, Eli Lilly and Company. All rights reserved. For more information, go to www.MOUNJARO.com or call 1-800-545-5979.
MOU-0009-MG-20260422
MOU-0010-MG-20260827

Unchanged: Boxed warning, Dosage forms and strengths, Contraindications, Drug interactions, Overdosage, Description, Nonclinical toxicology, Mounjaro Single-Dose Pen Instructions for Use, Mounjaro Single-Dose Vial Instructions for Use, Mounjaro Multiple-Dose Vial Instructions for Use, Mounjaro KwikPen Multi-Dose Pen Instructions for Use, PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 2.5 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 5 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 7.5 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 10 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 12.5 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 15 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Single-Dose Vial - 2.5 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Single-Dose Vial - 5 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Single-Dose Vial - 7.5 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Single-Dose Vial - 10 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Single-Dose Vial - 12.5 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Single-Dose Vial - 15 mg/0.5 mL Dose, PACKAGE LABEL - Mounjaro Multi-Dose Vial - 2.5 mg/0.6 mL Dose (10 mg/2.4 mL [4.17 mg/mL]), PACKAGE LABEL - Mounjaro Multi-Dose Vial - 5 mg/0.6 mL Dose (20 mg/2.4 mL [8.33 mg/mL]), PACKAGE LABEL - Mounjaro Multi-Dose Vial - 7.5 mg/0.6 mL Dose (30 mg/2.4 mL [12.5 mg/mL]), PACKAGE LABEL - Mounjaro Multi-Dose Vial - 10 mg/0.6 mL Dose (40 mg/2.4 mL [16.7 mg/mL]), PACKAGE LABEL - Mounjaro Multi-Dose Vial - 12.5 mg/0.6 mL Dose (50 mg/2.4 mL [20.8 mg/mL]), PACKAGE LABEL - Mounjaro Multi-Dose Vial - 15 mg/0.6 mL Dose (60 mg/2.4 mL[25 mg/mL]), Package label.

Every version

22 versions of set d2d7da5d-ad07-4228-955f-cf7e355c8cc0, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.